A humanized monoclonal antibody directed against the human chemokine receptor 2 (CCR2), with potential antiangiogenic, immunomodulating, antimetastatic, and antineoplastic activities. Plozalizumab binds to CCR2 and prevents binding of the endothelium-derived CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and so inhibition of angiogenesis, tumor cell migration, and tumor cell proliferation. In addition, this agent may reduce levels of C-reactive protein (CRP). The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation.

A substance being studied as a treatment for atherosclerosis (a build-up of fat in the arteries). It is also being studied in the treatment of cancers that spread to the bone. Anti-CCR2 monoclonal antibody MLN1202 binds to a protein called CCR2, which is found on the surface of certain bone cells, white blood cells, and cancer cells. Anti-CCR2 monoclonal antibody MLN1202 blocks the action of a substance that is involved in keeping healthy bone mass. It may help keep the cancer cells from spreading to and growing in the bone. It is a type of monoclonal antibody.